Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Pulmonary hypertension associated with idiopathic interstitial pneumonia: is effective pharmacotherapy an impossible dream?

Meyer KC.

Lancet Respir Med. 2019 Sep;7(9):727-728. doi: 10.1016/S2213-2600(19)30266-8. Epub 2019 Aug 12. No abstract available.

PMID:
31416766
2.

High Lung Allocation Scores and Lung Transplantation: Is There a Ceiling?

Meyer KC.

Chest. 2019 Jul;156(1):9-11. doi: 10.1016/j.chest.2019.02.330. No abstract available.

PMID:
31279378
3.

Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.

Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Moran D, Santin-Janin H, Aubin F, Mulder GJ, Gupta R, Richeldi L.

Lancet Respir Med. 2019 Aug;7(8):657-664. doi: 10.1016/S2213-2600(19)30172-9. Epub 2019 May 20.

PMID:
31122893
4.

Origins of the Inverse Electrocaloric Effect.

Grünebohm A, Ma YB, Marathe M, Xu BX, Albe K, Kalcher C, Meyer KC, Shvartsman VV, Lupascu DC, Ederer C.

Energy Technol (Weinh). 2018 Aug;6(8):1491-1511. doi: 10.1002/ente.201800166. Epub 2018 Aug 8. Review.

5.

Mycophenolate therapy in interstitial pneumonia with autoimmune features: a cohort study.

McCoy SS, Mukadam Z, Meyer KC, Kanne JP, Meyer CA, Martin MD, Sampene E, Aesif SW, Rice LN, Bartels CM.

Ther Clin Risk Manag. 2018 Nov 1;14:2171-2181. doi: 10.2147/TCRM.S173154. eCollection 2018.

6.

Balancing fairness and efficacy in lung allocation for transplantation: unfinished business.

Meyer KC.

Thorax. 2019 Jan;74(1):16-17. doi: 10.1136/thoraxjnl-2018-212634. Epub 2018 Nov 16. No abstract available.

PMID:
30446619
7.

Recent advances in lung transplantation.

Meyer KC.

F1000Res. 2018 Oct 23;7. pii: F1000 Faculty Rev-1684. doi: 10.12688/f1000research.15393.1. eCollection 2018. Review.

8.

Scleroderma with Fibrosing Interstitial Lung Disease: Where Do We Stand?

Meyer KC.

Ann Am Thorac Soc. 2018 Nov;15(11):1273-1275. doi: 10.1513/AnnalsATS.201808-544ED. No abstract available.

PMID:
30382781
9.

Lung disease associated with occupational styrene exposure.

Meyer KC, Sharma B, Kaufmann B, Kupper A, Hodgson M.

Am J Ind Med. 2018 Jun 13. doi: 10.1002/ajim.22867. [Epub ahead of print]

PMID:
29900554
10.

Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.

Raghu G, van den Blink B, Hamblin MJ, Brown AW, Golden JA, Ho LA, Wijsenbeek MS, Vasakova M, Pesci A, Antin-Ozerkis DE, Meyer KC, Kreuter M, Santin-Janin H, Mulder GJ, Bartholmai B, Gupta R, Richeldi L.

JAMA. 2018 Jun 12;319(22):2299-2307. doi: 10.1001/jama.2018.6129.

11.

Specific Donor HLA-DR Types Correlate With Altered Susceptibility to Development of Chronic Lung Allograft Dysfunction.

Haynes LD, Julliard WA, Mezrich JD, Leverson G, Meyer KC, Burlingham WJ.

Transplantation. 2018 Jul;102(7):1132-1138. doi: 10.1097/TP.0000000000002107.

12.

Role of pirfenidone in the management of pulmonary fibrosis.

Meyer KC, Decker CA.

Ther Clin Risk Manag. 2017 Apr 3;13:427-437. doi: 10.2147/TCRM.S81141. eCollection 2017. Review.

13.

Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis.

Meyer KC.

Expert Rev Respir Med. 2017 May;11(5):343-359. doi: 10.1080/17476348.2017.1312346. Epub 2017 Apr 10. Review.

PMID:
28345383
14.

Pulmonary fibrosis, part II: state-of-the-art patient management.

Meyer KC.

Expert Rev Respir Med. 2017 May;11(5):361-376. doi: 10.1080/17476348.2017.1312347. Epub 2017 Apr 13. Review.

PMID:
28345369
15.

Peripheral Blood Gene Expression Changes Associated With Primary Graft Dysfunction After Lung Transplantation.

Diamond JM, Cantu E, Porteous MK, Suzuki Y, Meyer KC, Lederer DJ, Milewski RK, Arcasoy S, D'Ovidio F, Bacchetta M, Sonett JR, Singh G, Costa J, Tobias JW, Rodriguez H, Van Deerlin VM, Olthoff KM, Shaked A, Chang BL, Christie JD; Clinical Trials in Organ Transplantation (CTOT)-03 Investigators.

Am J Transplant. 2017 Jul;17(7):1770-1777. doi: 10.1111/ajt.14209. Epub 2017 Feb 17.

16.

Great expectations for simtuzumab in IPF fall short.

Meyer KC.

Lancet Respir Med. 2017 Jan;5(1):2-3. doi: 10.1016/S2213-2600(16)30420-9. Epub 2016 Dec 7. No abstract available.

PMID:
27939077
17.

Lung transplantation for high-risk patients with idiopathic pulmonary fibrosis.

De Oliveira NC, Julliard W, Osaki S, Maloney JD, Cornwell RD, Sonetti DA, Meyer KC.

Sarcoidosis Vasc Diffuse Lung Dis. 2016 Oct 7;33(3):235-241.

PMID:
27758988
18.

The Perioperative Lung Transplant Virome: Torque Teno Viruses Are Elevated in Donor Lungs and Show Divergent Dynamics in Primary Graft Dysfunction.

Abbas AA, Diamond JM, Chehoud C, Chang B, Kotzin JJ, Young JC, Imai I, Haas AR, Cantu E, Lederer DJ, Meyer KC, Milewski RK, Olthoff KM, Shaked A, Christie JD, Bushman FD, Collman RG.

Am J Transplant. 2017 May;17(5):1313-1324. doi: 10.1111/ajt.14076. Epub 2016 Nov 4.

19.

Laser Direct Write Synthesis of Lead Halide Perovskites.

Chou SS, Swartzentruber BS, Janish MT, Meyer KC, Biedermann LB, Okur S, Burckel DB, Carter CB, Kaehr B.

J Phys Chem Lett. 2016 Oct 6;7(19):3736-3741. Epub 2016 Sep 12.

PMID:
27593712
20.

Multidisciplinary discussions and interstitial lung disease diagnosis: how useful is a meeting of the minds?

Meyer KC.

Lancet Respir Med. 2016 Jul;4(7):529-531. doi: 10.1016/S2213-2600(16)30065-0. Epub 2016 May 11. No abstract available.

PMID:
27180020
21.

Timing and Frequency of Unplanned Readmissions After Lung Transplantation Impact Long-Term Survival.

Lushaj E, Julliard W, Akhter S, Leverson G, Maloney J, Cornwell RD, Meyer KC, DeOliveira N.

Ann Thorac Surg. 2016 Aug;102(2):378-84. doi: 10.1016/j.athoracsur.2016.02.083. Epub 2016 May 4.

PMID:
27154148
22.

Passenger Leukocytes Revisited: One Passenger That Refuses to Leave the Airspace.

Burlingham WJ, Braun RK, Meyer KC.

Am J Transplant. 2016 Aug;16(8):2247-9. doi: 10.1111/ajt.13842. Epub 2016 Jun 9. No abstract available.

23.

Diagnosis and management of bronchiolitis obliterans syndrome following lung or hematopoietic cell transplantation.

Meyer KC.

Expert Rev Respir Med. 2016 Jun;10(6):599-602. doi: 10.1586/17476348.2016.1162717. Epub 2016 Mar 21. No abstract available.

PMID:
26950825
24.

The presence or severity of pulmonary hypertension does not affect outcomes for single-lung transplantation.

Julliard WA, Meyer KC, De Oliveira NC, Osaki S, Cornwell RC, Sonetti DA, Maloney JD.

Thorax. 2016 May;71(5):478-80. doi: 10.1136/thoraxjnl-2015-207354. Epub 2015 Nov 30.

25.

Acute fibrinous and organising pneumonia following lung transplantation is associated with severe allograft dysfunction and poor outcome: a case series.

Meyer KC, Bierach J, Kanne J, Torrealba JR, De Oliveira NC.

Pneumonia (Nathan). 2015 Dec 1;6:67-76. doi: 10.15172/pneu.2015.6/648. eCollection 2015.

26.

Management of Idiopathic Pulmonary Fibrosis in the Elderly Patient: Addressing Key Questions.

Meyer KC, Danoff SK, Lancaster LH, Nathan SD.

Chest. 2015 Jul;148(1):242-252. doi: 10.1378/chest.14-2475. Review.

PMID:
26149553
27.

Gastroesophageal reflux and lung disease.

Meyer KC.

Expert Rev Respir Med. 2015 Aug;9(4):383-5. doi: 10.1586/17476348.2015.1060858. Epub 2015 Jun 23.

PMID:
26104973
28.

An international ISHLT/ATS/ERS clinical practice guideline: summary for clinicians. Bronchiolitis obliterans syndrome complicating lung transplantation.

Welsh CH, Wang TS, Lyu DM, Orr J, Meyer KC, Glanville AR, Verleden GM, Wilson KC, Thomson CC, The American Thoracic Society Implementation Task Force.

Ann Am Thorac Soc. 2015 Jan;12(1):118-9. doi: 10.1513/AnnalsATS.201410-471CME. Review. No abstract available.

PMID:
25635657
29.

Diagnosis and management of interstitial lung disease.

Meyer KC.

Transl Respir Med. 2014 Feb 13;2:4. doi: 10.1186/2213-0802-2-4. eCollection 2014. Review.

30.

An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome.

Meyer KC, Raghu G, Verleden GM, Corris PA, Aurora P, Wilson KC, Brozek J, Glanville AR; ISHLT/ATS/ERS BOS Task Force Committee; ISHLT/ATS/ERS BOS Task Force Committee.

Eur Respir J. 2014 Dec;44(6):1479-503. doi: 10.1183/09031936.00107514. Epub 2014 Oct 30.

31.

Mechanically encoded cellular shapes for synthesis of anisotropic mesoporous particles.

Meyer KC, Coker EN, Bolintineanu DS, Kaehr B.

J Am Chem Soc. 2014 Sep 24;136(38):13138-41. doi: 10.1021/ja506718z. Epub 2014 Sep 10.

PMID:
25170802
32.

IPF clinical trial design and endpoints.

Nathan SD, Meyer KC.

Curr Opin Pulm Med. 2014 Sep;20(5):463-71. doi: 10.1097/MCP.0000000000000091. Review.

33.

Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata.

Bertolini M, Zilio F, Rossi A, Kleditzsch P, Emelianov VE, Gilhar A, Keren A, Meyer KC, Wang E, Funk W, McElwee K, Paus R.

PLoS One. 2014 May 15;9(5):e94260. doi: 10.1371/journal.pone.0094260. eCollection 2014.

34.

Neutrophil elastase-mediated increase in airway temperature during inflammation.

Schmidt A, Belaaouaj A, Bissinger R, Koller G, Malleret L, D'Orazio C, Facchinelli M, Schulte-Hubbert B, Molinaro A, Holst O, Hammermann J, Schniederjans M, Meyer KC, Damkiaer S, Piacentini G, Assael B, Bruce K, Häußler S, LiPuma JJ, Seelig J, Worlitzsch D, Döring G.

J Cyst Fibros. 2014 Dec;13(6):623-31. doi: 10.1016/j.jcf.2014.03.004. Epub 2014 Apr 6.

35.

Immunosuppressive agents and interstitial lung disease: what are the risks?

Meyer KC.

Expert Rev Respir Med. 2014 Jun;8(3):263-6. doi: 10.1586/17476348.2014.880054. Epub 2014 Mar 20.

PMID:
24649876
36.

The clinical utility of bronchoalveolar lavage in interstitial lung disease - is it really useful?

Meyer KC.

Expert Rev Respir Med. 2014 Apr;8(2):133-5. doi: 10.1586/17476348.2014.879827. Epub 2014 Jan 22.

PMID:
24450398
37.

A new classification system for chronic lung allograft dysfunction.

Verleden GM, Raghu G, Meyer KC, Glanville AR, Corris P.

J Heart Lung Transplant. 2014 Feb;33(2):127-33. doi: 10.1016/j.healun.2013.10.022. Epub 2013 Oct 24.

PMID:
24374027
38.

COPD 2013: an update on treatment and newly approved medications for pharmacists.

Meyer KC.

J Am Pharm Assoc (2003). 2013 Nov-Dec;53(6):e219-29; quiz e230-1. doi: 10.1331/JAPhA.2013.13535. Review.

PMID:
24185438
39.

Dysregulation of galectin-3. Implications for Hermansky-Pudlak syndrome pulmonary fibrosis.

Cullinane AR, Yeager C, Dorward H, Carmona-Rivera C, Wu HP, Moss J, O'Brien KJ, Nathan SD, Meyer KC, Rosas IO, Helip-Wooley A, Huizing M, Gahl WA, Gochuico BR.

Am J Respir Cell Mol Biol. 2014 Mar;50(3):605-13. doi: 10.1165/rcmb.2013-0025OC.

40.
41.

The immune system of mouse vibrissae follicles: cellular composition and indications of immune privilege.

Bertolini M, Meyer KC, Slominski R, Kobayashi K, Ludwig RJ, Paus R.

Exp Dermatol. 2013 Sep;22(9):593-8. doi: 10.1111/exd.12205.

PMID:
23947674
42.

Reply: performing bronchoalveolar lavage as per the ATS guidelines 2012.

Meyer KC, Raghu G.

Am J Respir Crit Care Med. 2013 Jul 1;188(1):113-4. doi: 10.1164/rccm.201301-0163LE. No abstract available.

PMID:
23815727
43.

Lactate levels in airways of patients with cystic fibrosis and idiopathic pulmonary fibrosis.

Worlitzsch D, Meyer KC, Döring G.

Am J Respir Crit Care Med. 2013 Jul 1;188(1):111. doi: 10.1164/rccm.201211-2042LE. No abstract available.

PMID:
23815725
44.

Lung transplantation.

Meyer KC.

F1000Prime Rep. 2013 May 1;5:16. doi: 10.12703/P5-16. Print 2013.

45.

Reply: The clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease.

Meyer KC, Raghu G.

Am J Respir Crit Care Med. 2013 Apr 1;187(7):777-8. No abstract available.

PMID:
23540881
46.

Safety of and cellular response to segmental bronchoprovocation in allergic asthma.

Denlinger LC, Kelly EA, Dodge AM, McCartney JG, Meyer KC, Cornwell RD, Jackson MJ, Evans MD, Jarjour NN.

PLoS One. 2013;8(1):e51963. doi: 10.1371/journal.pone.0051963. Epub 2013 Jan 16.

47.

Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

Baughman RP, Meyer KC, Nathanson I, Angel L, Bhorade SM, Chan KM, Culver D, Harrod CG, Hayney MS, Highland KB, Limper AH, Patrick H, Strange C, Whelan T.

Chest. 2012 Nov;142(5):e1S-e111S. doi: 10.1378/chest.12-1044.

48.

Executive summary: monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

Baughman RP, Meyer KC, Nathanson I, Angel L, Bhorade SM, Chan KM, Culver D, Harrod CG, Hayney MS, Highland KB, Limper AH, Patrick H, Strange C, Whelan T.

Chest. 2012 Nov;142(5):1284-1288. doi: 10.1378/chest.12-1075. No abstract available.

49.

Immunosuppressive therapy for autoimmune lung diseases.

Meyer KC, Bierach J.

Immunol Allergy Clin North Am. 2012 Nov;32(4):633-69. doi: 10.1016/j.iac.2012.07.001. Epub 2012 Sep 4. Review.

PMID:
23102070
50.

Effect of prophylactic supplementation with grape polyphenolics on endotoxin-induced serum secretory phospholipase A2 activity in rats.

Tsao FH, Culver BJ, Pierre JF, Shanmuganayagam D, Patten CC Jr, Meyer KC.

Comp Med. 2012 Aug;62(4):271-8.

Supplemental Content

Loading ...
Support Center